421TiP - Phase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with fi...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Central Nervous System Malignancies
Surgery and/or Radiotherapy of Cancer
Presenter Patrick Wen
Citation Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367
Authors P.Y. Wen1, K. Shih2, D. Schiff3, R. Brachmann4, R. Weitzman4, T. Cloughesy5
  • 1Dana-farber Cancer Institute, Harvard Medical School, 02215 - Boston/US
  • 2Neuro-oncology, Sarah Cannon Research Insititute, 37205 - Nashville/US
  • 3Neurology, University of Virginia Health System, Charlottesville/US
  • 4Clinical Development, BeiGene USA, Inc, 94608 - Emeryville/US
  • 5Neurology-oncology, University of California Los Angeles, Los Angeles/US



Poly (ADP-ribose) polymerase (PARP) proteins are a family of DNA binding and repair proteins and are thought to play a key role in the base excision repair of DNA damage generated by TMZ. In glioblastoma (GB) cells, pharmacological modulation of PARP activity increased growth inhibition induced by TMZ in both p53-wild type and-mutant GB cells lowering the TMZ IC50. RT used in the clinical treatment of GB generates mostly single-strand breaks (SSBs). In non-replicating cells PARP inhibition only delays the repair of SSBs induced by radiation with a minimal impact on cell survival. On the contrary, PARP inhibition markedly enhances radiosensitivity of proliferating cells generating double-strand breaks. Thus, PARP inhibitors have the potential to increase the therapeutic index of RT by increasing DNA damage mainly in highly replicating tumor cells, but sparing non-cycling normal tissues. BGB-290, a potent and selective inhibitor of PARP1/2, has demonstrated potent PARP trapping, brain penetrance and antitumor activity in preclinical intracranial xenograft models.

Trial design

This open-label, dose-escalation/dose-expansion Phase 1b/2 study was designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of BGB-290 at the recommended Phase 2 dose (60 mg PO BID) in combination with RT and/or TMZ. The Phase 1b component will consist of 3 dose-escalation arms. Arm A: BGB-290 will be combined with RT in patients with first-line GB with unmethylated MGMT promoter (‘unmethylated GB’); Arm B: BGB-290 will be combined with both TMZ and RT in patients with first-line unmethylated GB; Arm C: BGB-290 will be combined with increasing doses of TMZ in patients with recurrent/refractory methylated or unmethylated GB. Once a recommended Phase 2 regimen has been established, up to 60 patients may be enrolled in the dose-expansion (Phase 2) cohort for that arm. In Arm C, 2 expansion cohorts with up to 60 patients each may be opened: 1 for unmethylated GB and 1 for methylated GB.

Clinical trial identification

Legal entity responsible for the study

Beigene Ltd.


Beigene Ltd.


P. Wen: Grants, personal fees, and/or non-financial support from Agios, Angiochem, AstraZeneca, Genentech/Roche, GlaxoSmithKline, Immunocellular Therapeutics, Karyopharm, Merck, Novartis, and other biotech/pharma companies outside submitted work. D. Schiff: Grants from Cavion & Celldex, personal fees from VBI, Orbus, Monteris, Genentech-Roche, Heron Pharmaceuticals, Midatech, and Oxigene, outside the submitted work. R. Brachmann: Employee of Beigene USA, Inc. R. Weitzman: Consultant to BeiGene. T. Cloughesy: Personal fees from Pfizer, Tocagen, Roche, Novocure, Nektar, VBL, ABBVIE, Upshire Smith, Notable Labs, Oxigene, NewGen, Agios, Cortice, MedQia, PRoNai,and other pharma/biotech companies, outside the submitted work. All other authors have declared no conflicts of interest.